346672-98-8

Upstream product

• 351-35-9 3-(trifluoromethyl)phenylacetic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 30934-66-8 1-phenyl-2-<3-(trifluoromethyl)phenyl>-1-ethanone 
• 945227-58-7 C₁₄H₁₀F₃NO 
• 73718-79-3 [2-oxo-3-(3-trifluoromethyl-phenyl)-propyl]-phosphonic acid dimethyl ester 
• 1000771-10-7 1-[3-(trifluoromethyl)phenyl]but-3-en-2-one 
• 533893-74-2 ethyl 7-[(2R)-2-{(1E,3S)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-buten-1-yl}-5-oxo-1-pyrrolidinyl]heptanoate 
• 533893-84-4 7-{(R)-2-Oxo-5-[(E)-3-oxo-4-(3-trifluoromethyl-phenyl)-but-1-enyl]-pyrrolidin-1-yl}-heptanoic acid ethyl ester 
• 494222-26-3 4-[(2-{(2R)-2-[(1E,3S)-3-hydroxy-4-(3-trifluoromethylphenyl)but-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)sulfanyl]butanoic acid 
• 1365392-10-4 C₂₂H₂₈F₃NO₄S 
• 945226-71-1 C₁₁H₁₁F₃O 

Relevant academic research and scientific papers

6-Membered heterocyclic compound and use thereof

A compound represented by the general formula (I) or a salt thereof: [T represents oxygen atom and the like; V represents CH2 and the like; RO1 to RO4 represent hydrogen atom and the like; A represents a linear alkylene group or linear alkenylene group having 2 to 8 carbon atoms and the like; D represents carboxyl group and the like; X represents ethylene group, trimethylene group and the like; E represents —CH(OH)— group and the like; and W represent —U1—(RW1)(RW2)—U2—U3 group (U1 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; RW1 and RW2 represent hydrogen atom and the like; U2 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; and U3 represent an alkyl group having 1 to 8 carbon atoms and the like), or a residue of a carbon ring or heterocyclic compound], which can be utilized as an active ingredient of medicaments effective for prophylactic and/or therapeutic treatment of skeletal diseases such as osteoporosis and fracture, glaucoma, ulcerative colitis and the like.

Synthesis and evaluation of novel pyrazolidinone analogs of PGE2 as EP2 and EP4 receptors agonists

Replacement of the hydroxy cyclopentanone ring in PGE2 with chemically more stable heterocyclic rings and substitution of the unsaturated α-alkenyl chain with a metabolically more stable phenethyl chain led to the development of potent and selective analogs of PGE2. Compound 10f showed the highest potency and selectivity for EP4 the receptor.